To wrap up, we have shown for the first time that Arborinine showed inhibitory effect on ccRCC via KDM1A/UBE2O signaling, and a detailed regulatory mechanism warrants further investigation. Here, KDM1A is linked to nonpapillary renal cell carcinoma.